blood advances

American Society of Hematology
2021 L Street NW, Suite 900,
Washington, DC 20036
Phone: 202-776-0544 | Fax 202-776-0545
bloodadvances@hematology.org

# The Dosing of Ibrutinib and Related Bruton's Tyrosine Kinase Inhibitors: Eliminating the Use of Brute Force

Tracking no: ADV-2022-007793-CR2

Mark Ratain (The University of Chicago, United States) Ian tannock (Princess Margaret Cancer Centre, Canada) Allen Lichter (Optimal Cancer Care Alliance, United States)

**Abstract:**

**Conflict of interest:** COI declared - see note

**COI notes:** M.J.R reports personal fees from Apotex, Aptevo, Arvinas Operations, Ayala Pharma, Bayer Pharmaceuticals, bluebird bio, Credit Suisse, Eagle Pharmaceuticals, EMD Serono, Emerson Lake Safety, EQRx, Sandoz, Actavis, Aurobindo, Dr. Reddy's Laboratories, Mylan, Hetero Labs, Breckenridge Pharmaceutical, Teva, Mereo, T3 Pharmaceuticals, Shilpa, Accord, MSN, Natco, Oncovalent Therapeutics, and Genentech; institutional research funding from Bristol-Myers Squibb, Xencor, and AbbVie; stock options in SAB Biotherapeutics; and a leadership role in the Optimal Cancer Care Alliance (director and treasurer). I.F.T. reports a leadership role in the Optimal Cancer Care Alliance (director and chairman of the board). A.L.S. reports stock options in Cellworks and Ascentage Pharmaceuticals; and leadership roles in Cellworks (director), Ascentage Pharmaceuticals (Clinical Advisory Board member), the Optimal Cancer Care Alliance (director), CancerLinQ (director), and the Learning Health Community (director).

**Preprint server:** No;

**Author contributions and disclosures:** M.J.R. conceived the study and wrote the manuscript; I.F.T. performed statistics and provided critical input; A.L.S. provided critical input; and all authors approved the final version of the manuscript.

**Non-author contributions and disclosures:** No;

**Agreement to Share Publication-Related Data and Data Sharing Statement:** N/A

**Clinical trial registration information (if any):**

# The Dosing of Ibrutinib and Related Bruton's Tyrosine Kinase Inhibitors: Eliminating the Use of Brute Force

Short Title: Dosing of BTK Inhibitors

Mark J. Ratain [1,2], Ian F. Tannock [2,3], and Allen S. Lichter [2]

[1] Section of Hematology/Oncology, Department of Medicine, The University of Chicago, [2] The Optimal Cancer Care Alliance, and [3] Princess Margaret Cancer Centre, University of Toronto

Corresponding Author:

Mark J. Ratain, MD

5841 S. Maryland Avenue

MC2115

Chicago, IL 60637

email: mjr1@uchicago.edu

phone: 773-795-5453

fax: 773-702-3969

Contact the corresponding author for data sharing: mjr1@uchicago.edu.

Word count 1,504

Figures 0, Tables 1

References 37

The Bruton's tyrosine kinase (BTK) inhibitors are important drugs for the management of chronic lymphocytic leukemia (CLL) and related lymphoproliferative disorders,[1] and clinical trials are ongoing in various autoimmune diseases (*e.g.*, rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis).[2, 3] While this article focuses on the four irreversible BTK inhibitors approved in the United States or Japan, there are many other BTK inhibitors in clinical development. While most of these investigational agents (and all approved agents) are irreversible inhibitors, there are several reversible inhibitors (*e.g.*, pirtobrutinib[6]).

Ibrutinib was the first BTK inhibitor approved for marketing, and currently has six indications, including multiple lymphoproliferative disorders and chronic graft versus host disease. Ibrutinib binds to the cysteine residue resulting from the C481S mutation in BTK.[7] The approved ibrutinib dose is 420 mg daily for most indications, but 560 mg daily for mantle-cell lymphoma (MCL) and marginal zone lymphoma. However, the initial 2013 review by the Food and Drug Administration (FDA) noted that doses above 2.5 mg/kg daily appeared excessive: "We recommend you evaluate lower doses of ibrutinib in future clinical development as data from the Phase 1 trial PCYC-04753 showed that maximum BTK occupancy and maximum response were achieved at doses of $\geq$2.5 mg/kg."[8] Despite this FDA recommendation, all subsequent trials of ibrutinib were conducted using doses of 420-560 mg daily. The company that markets ibrutinib, Pharmacyclics, obtained method of treatment patents for its multiple indications, all of which exclude the lower dose recommended by FDA, which has been described as "negative innovation."[9]

The dose-finding study of ibrutinib and venetoclax published in this journal by Portell and colleagues concluded that the optimal doses for MCL were ibrutinib 420 mg and venetoclax 200 mg daily.[10] This conclusion was based on a dose-limiting toxicity rate of $\leq$25% and "maximizing" the objective response rate (ORR) at 2 months. This definition is inconsistent with principles of drug development, now embodied in FDA's Project Optimus.[11, 12] There is no evidence to support the conclusion that these

doses are optimal, since the ORR was no higher than at a lower dose. If one combines cohorts receiving different venetoclax doses, there were 21 patients treated with ibrutinib 420 mg daily and 10 patients treated with 280 mg daily (Table 1). The small number of patients does not allow a reliable conclusion as to the optimal ibrutinib dose, but the lower dose appears equally effective and less toxic.

Ibrutinib causes a high incidence of atrial fibrillation (AF), which is not due to inhibition of BTK. Patients with X-linked agammaglobulinemia (XLA), which is due to inactivating mutations in *BTK*, do not experience atrial fibrillation. Xiao and colleagues developed a mouse model for ibrutinib cardiotoxicity, demonstrating that inducible AF developed after four weeks of treatment and was associated with atrial fibrosis and dilatation. Ibrutinib, but not acalabrutinib, induces AF and affects atrial and sinoatrial node myocytes.[13, 14] Based on comparison of the non-BTK targets of these two BTK inhibitors, Xiao and colleagues hypothesized that AF was due to inhibition of Fyn, mitogen-activated protein/extracellular signal regulated protein kinase 5 (MEK5) or C-terminal Src kinase (CSK). They demonstrated that cardiac knockout of CSK produced similar effects to ibrutinib. Thus, CSK inhibition by ibrutinib appears responsible for the drug's cardiotoxicity. Of particular concern is the risk of induction of AF by ibrutinib, followed by a stroke, which had a mortality rate of 18% in a 2019 analysis of 303 cardiovascular deaths in the World Health Organization pharmacovigilance database (VigiBase).[15]

Some patients in clinical trials of acalabrutinib have developed AF, but there is minimal evidence that this is caused directly by the drug. In a randomized controlled trial for people with CLL, there was a 3.6% incidence of AF, higher than in the non-BTK control arm (0.6%). However, the median duration of observation for patients randomized to acalabrutinib was approximately 5-fold longer than for the control arm, and thus the AF is unlikely due to the antileukemic therapy. Furthermore, there have been no concerns about cardiac toxicity of BTK inhibitors being developed for non-oncology indications.[16-21]

Ibrutinib frequently causes bleeding, which is also probably not due to BTK inhibition, since it does not occur with all BTK inhibitors[22], and XLA patients do not manifest a bleeding diathesis. Many of the BTK inhibitors also inhibit Tec kinase, which regulates platelet activation in the absence of BTK activity.[23, 24] Inhibition of CSK may also be responsible for ibrutinib-associated bleeding, since CSK plays a major role in regulation of platelet homeostasis.[25-27]

We do not suggest that hematologists abandon ibrutinib, a drug that has been prescribed to many patients without mishap. However, if BTK inhibition is desirable and CSK inhibition is undesirable, the goal should be to administer a dose that adequately inhibits BTK, while minimizing inhibition of CSK. That is readily achievable, as ibrutinib's $IC_{50}$ for BTK is 0.5 nM, whereas its $IC_{50}$ for CSK is 2.3 nM, a 4.6-fold therapeutic index.[7] Lower doses of ibrutinib (*e.g.*, 140 mg daily, consistent with the 2013 FDA recommendation) would be expected to maintain BTK inhibition and efficacy, while eliminating or reducing the risks of AF (and possibly also hemorrhage).[28] A small pilot study has demonstrated that ibrutinib's BTK occupancy and pharmacodynamics are unaffected by reduction to 140-280 mg daily.[29]

Hematologists and oncologists should abandon the notion of using toxicity to determine the optimal dose of molecular targeted agents – particularly covalent irreversible cysteine-directed binders, as exemplified by the Portell study[10] and the development of sotorasib (approved in 2021 for KRAS G12C-mutant lung cancer).[30] The optimal dose should be reassessed for other irreversible BTK inhibitors including acalabrutinib (approved in multiple countries since 2017), zanubrutinib (approved in multiple countries since 2019), and tirabrutinib (approved in Japan since 2020).

Acalabrutinib obtained its approval for MCL at a dose of 100 mg twice daily. While doses up to 400 mg daily were investigated in the phase 1 trial, 100 mg twice daily appeared to yield superior pharmacological and clinical results to daily dosing in this nonrandomized assessment.[31] However, there is no relationship between acalabrutinib (and/or its active metabolite, ACP-5862) exposure and efficacy

(or adverse events) at the approved dose, which suggests that efficacy plateaus at an exposure less than that achieved with 100 mg twice daily.[32] Lower doses of acalabrutinib would likely maintain efficacy, although trials evaluating lower doses are not feasible given that the only available formulation is a 100 mg capsule.

Zanubrutinib was approved initially for MCL at a dose of either 160 mg twice daily or 320 mg daily. In the phase 1 trial, responses and complete BTK occupancy were observed at doses of 40 mg daily (the lowest dose evaluated) and higher,[33] without evidence of a dose-response relationship. Forty percent of patients receiving zanubrutinib 160 mg twice daily in a phase 3 trial comparing it to ibrutinib experienced at least one serious adverse event. Zanubrutinib is formulated as 80 mg capsules, and trials exploring lower dosages (e.g., 80 mg daily or twice daily) should be undertaken.

Tirabrutinib is available in Japan for the treatment of primary central nervous system lymphoma (PCNSL), at a dose of 480 mg once daily, administered as six 80 mg tablets under fasting conditions.[33] A phase 1 study in patients with relapsed or refractory lymphoma or CLL, demonstrated that all three patients receiving a dose of 160 mg (the lowest dose studied) responded, with one patient experiencing a durable complete response.[34] A subsequent trial for patients with PCNSL, using a dose of 320-480 mg once daily, demonstrated a 64% response rate (34% complete responses) without evidence of dose-response.[35] In contrast, there was a dose-toxicity relationship. Pharmacokinetic studies demonstrated that the unbound concentration in cerebrospinal fluid was comparable to that in plasma. The dose of 480 mg appears excessive, and doses of 160 mg daily or less should be investigated, ideally with food ( since food increases absorption[36]).

While the newer irreversible BTK inhibitors do not cause AF due to CSK inhibition, their development has been equally flawed, and unfortunately accepted by global regulatory authorities. For example, the

phase 1 study of pirtobrutinib concluded that the recommended phase 2 dose was 200 mg daily, despite clear evidence that a dose of 25 mg was active[6].

While we acknowledge that atrial fibrillation and bleeding are widely believed to be due to BTK inhibition, we believe the preponderance of the evidence refutes this conclusion, particularly the lack of such toxicities in clinical trials of BTK inhibitors in non-malignant diseases[16-21]. The definitive test would be to rigorously evaluate lower doses of ibrutinib – and perhaps other BTK inhibitors, to assess the relationship of drug dose (and exposure) to these probable off-target toxicities, given that there does not appear to be a relationship between dose or exposure and efficacy[8, 28]. Such studies are of increasing importance, given the advent of FDA's Project Optimus, since the historical paradigm of using toxicity to determine the optimal dose is no longer acceptable.[12, 37] The deployment of brute force in the development of targeted agents will no longer be condoned, to the great benefit of patients with a wide variety of malignant diseases.



**Acknowledgement**

**Contribution:** M.J.R. conceived the study and wrote the first draft of the manuscript; I.F.T. and A.L.S. provided critical input; and all authors approved the final version of the manuscript.

**Conflict-of-interest disclosure:** M.J.R reports personal fees from Apotex, Aptevo, Arvinas Operations, Ayala Pharma, Bayer Pharmaceuticals, bluebird bio, Credit Suisse, Eagle Pharmaceuticals, EMD Serono, Emerson Lake Safety, EQRx, Sandoz, Actavis, Aurobindo, Dr. Reddy's Laboratories, Mylan, Hetero Labs, Breckenridge Pharmaceutical, Teva, Mereo, T3 Pharmaceuticals, Shilpa, Accord, MSN, Natco, Oncovalent Therapeutics, and Genentech; institutional research funding from Bristol-Myers Squibb, Xencor, and AbbVie; stock options in SAB Biotherapeutics; and a leadership role in the Optimal Cancer Care Alliance (director and treasurer). I.F.T. reports a leadership role in the Optimal Cancer Care Alliance (director

and chairman of the board). A.L.S. reports stock options in Cellworks and Ascentage Pharmaceuticals; and leadership roles in Cellworks (director), Ascentage Pharmaceuticals (Clinical Advisory Board member), the Optimal Cancer Care Alliance (director), CancerLinQ (director), and the Learning Health Community (director).

REFERENCES

1. Wen T, Wang J, Shi Y, Qian H, Liu P. Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances. *Leukemia*. 2021;35: 312-332.

2. Estupinan HY, Berglof A, Zain R, Smith CIE. Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. *Front Cell Dev Biol*. 2021;9: 630942.

3. Neys SFH, Hendriks RW, Corneth OBJ. Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies. *Front Cell Dev Biol*. 2021;9: 668131.

4. Ran F, Liu Y, Wang C, et al. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. *Eur J Med Chem*. 2022;229: 114009.

5. Ringheim GE, Wampole M, Oberoi K. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures. *Front Immunol*. 2021;12: 662223.

6. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. *Lancet*. 2021;397: 892-901.

7. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. *Proc Natl Acad Sci U S A*. 2010;107: 13075-13080.

8. CDER Application #205552Orig1s000 ibrutinib https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205552orig1s000clinpharmr.pdf Accessed 10 May 2022.

9. Feldman RC, Hyman DA, Price WN, Ratain MJ. Negative innovation: when patents are bad for patients. *Nat Biotechnol*. 2021;39: 914-916.

10. Portell CA, Wages NA, Kahl BS, et al. Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma. *Blood Adv*. 2022;6: 1490-1498.

11. FDA: Oncology Center of Excellence Project Optimus https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus Accessed 10 May 2022.

12. Shah M, Rahman A, Theoret MR, Pazdur R. The Drug-Dosing Conundrum in Oncology - When Less Is More. *N Engl J Med*. 2021;385: 1445-1447.

13. Tuomi JM, Bohne LJ, Dorey TW, et al. Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis. *J Am Heart Assoc*. 2021;10: e022369.

14. Xiao L, Salem JE, Clauss S, et al. Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. *Circulation*. 2020;142: 2443-2455.

15. Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular Toxicities Associated With Ibrutinib. *J Am Coll Cardiol*. 2019;74: 1667-1678.

16. Cohen S, Tuckwell K, Katsumoto TR, et al. Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study). *Arthritis Rheumatol*. 2020.

17. Isenberg D, Furie R, Jones NS, et al. Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. *Arthritis Rheumatol*. 2021;73: 1835-1846.

18. Kuter DJ, Efraim M, Mayer J, et al. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. *N Engl J Med*. 2022;386: 1421-1431.

19. Metz M, Sussman G, Gagnon R, et al. Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. *Nat Med*. 2021;27: 1961-1969.

20. Montalban X, Arnold DL, Weber MS, et al. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. *N Engl J Med*. 2019;380: 2406-2417.

21. Reich DS, Arnold DL, Vermersch P, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2021;20: 729-738.

22. von Hundelshausen P, Siess W. Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. *Cancers*. 2021;13: 1103.

23. Atkinson BT, Ellmeier W, Watson SP. Tec regulates platelet activation by GPVI in the absence of Btk. *Blood*. 2003;102: 3592-3599.

24. Bye AP, Unsworth AJ, Desborough MJ, et al. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. *Blood Adv*. 2017;1: 2610-2623.

25. Mori J, Nagy Z, Di Nunzio G, et al. Maintenance of murine platelet homeostasis by the kinase Csk and phosphatase CD148. *Blood*. 2018;131: 1122-1144.

26. Zhu J. Csk/CD148 and platelet SFK activation: a balancing act! *Blood*. 2018;131: 1042-1043.

27. Nagy Z, Mori J, Ivanova VS, Mazharian A, Senis YA. Interplay between the tyrosine kinases Chk and Csk and phosphatase PTPRJ is critical for regulating platelets in mice. *Blood*. 2020;135: 1574-1587.

28. Ratain MJ, Moslehi JJ, Lichter AS. Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation. *JAMA Oncol*. 2021;7: 177-178.

29. Chen LS, Bose P, Cruz ND, et al. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. *Blood*. 2018;132: 2249-2259.

30. Ratain MJ, Tannock IF, Lichter AS. Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message? *J Clin Oncol*. 2021;39: 3423-3426.

31. Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. *N Engl J Med*. 2016;374: 323-332.

32. Edlund H, Buil-Bruna N, Vishwanathan K, et al. Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies. *Br J Clin Pharmacol*. 2022;88: 2284-2296.

33. Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. *Blood*. 2019;134: 851-859.

34. Walter HS, Rule SA, Dyer MJ, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. *Blood*. 2016;127: 411-419.

35. Narita Y, Nagane M, Mishima K, et al. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. *Neuro Oncol*. 2021;23: 122-133.

36. PMDA: Report on the deliberation results. Tirabrutinib Hydrochloride https://www.pmda.go.jp/files/000237315.pdf Accessed 10 May 2022.

37. Tracey A. Oncologists, advocates, FDA call for an end to MTD and the “more is better” era in cancer drug dosing. *The Cancer Letter*. 2022;48.

Table 1. Reanalysis of data from Table 1 of Portell et al.[10]

| Ibrutinib dose | ORR (%) | CR (%) | DLT (%) |
|---|---|---|---|
| 280 | 8/10 (80) | 5/10 (50) | 0/10 (0) |
| 420 | 18/20 (90) | 8/19 (42) | 3/21 (14) |